Douglas Johnson

Mark Denison, MD, and Xiaotao Lu, MS, are among those on a new list of scientists whose papers have been cited the most frequently by other researchers. (photo by Erin O. Smith)
November 15, 2023

Twelve at Vanderbilt are among world’s highly cited researchers

Twelve current investigators at Vanderbilt University Medical Center and Vanderbilt University are on this year’s list of scientists whose papers have been cited the most frequently by other researchers.

By Bill Snyder
August 8, 2023

Chronic complications from immunotherapies more prevalent and persistent than previously shown among melanoma survivors

A Vanderbilt study has found that chronic immunotherapy-related complications are more prevalent and persistent than previously shown among melanoma survivors.

By Tom Wilemon
November 17, 2022

Several from VUMC among most highly cited researchers

Nine current faculty members of the Vanderbilt University School of Medicine have made this year’s list of scientists whose papers have been cited most frequently by other researchers.

By Bill Snyder
November 16, 2022

Cardiac antigen identified as mechanism for heart complication with immunotherapy-related myocarditis

Researchers from from Vanderbilt-Ingram Cancer Center have identified the mechanism for the deadly heart inflammation myocarditis.

By Tom Wilemon
Among those honored at last week’s event were (front row, from left) Pratik Pandharipande, MD, MSCI, Seth Smith, PhD, Kimberly Vinson, MD, Jessica Ancker, PhD, MPH, Nancy Davis, MD, Uyen Tran, MD, Tonia Rex, PhD, Adam Yock, PhD, DABR, Christopher Williams, MD, PhD, David Raiford, MD, (back row, from left) Adam Wright, PhD, Paul Moore, MD, Daniel Fabbri, PhD, John Penn, PhD, Rebecca Swan, MD, Alexander Gelbard, MD, Jennifer Lindsey, MD, Michael Savona, MD, Kathryn Lindley, MD, Sarah Jaser, PhD, and Douglas Johnson, MD, MSCI.
September 8, 2022

Directorships honor VUMC leaders and philanthropic partners

By Doug Campbell
August 18, 2022

Abramson, Eng, Johnson named to new VICC roles

Three physician researchers at Vanderbilt-Ingram Cancer Center are assuming additional leadership roles.

By Tom Wilemon
December 2, 2021

Directorships honor VUMC leaders and philanthropic partners

Ten Vanderbilt University Medical Center leaders from across the enterprise in clinical care, research, education and administration have been named as holders of endowed directorships.
By Doug Campbell
November 18, 2021

Seven from VUMC among most highly cited researchers

Seven Vanderbilt faculty members have made this year’s list of scientists whose papers have been cited most frequently by other researchers.
By Bill Snyder
March 25, 2021

Forty-three percent of melanoma patients have chronic complications from immunotherapies

Chronic side effects among melanoma survivors after treatment with anti-PD-1 immunotherapies are more common than previously recognized, according to a study published March 25 in JAMA Oncology.
By Tom Wilemon
September 25, 2019

Study identifies targeted therapy’s cardiac risks

After a recent study showed that chronic lymphocytic leukemia patients who received ibrutinib as a frontline treatment had a 7% death rate, a new study offers a clearer picture on the reasons for the deaths.
By Tom Wilemon
July 22, 2019

Encephalitis identified as rare toxicity of immunotherapy treatment

Researchers are chronicling rare but serious toxicities that may occur with immune checkpoint inhibitors, the most widely prescribed class of immunotherapies.
By Tom Wilemon
April 18, 2019

Medical Societies honor multiple Vanderbilt faculty

Several Vanderbilt faculty members were recently honored during the joint annual meeting of the Association of American Physicians (AAP) and American Society for Clinical Investigation (ASCI).
By Bill Snyder
November 15, 2018

Immunotherapies linked to specific heart complications

In the first large-scale analysis of cardiovascular complications linked to immune checkpoint inhibitors, Vanderbilt researchers have shown that heart and vessel complications include myocarditis, pericarditis, vasculitis and arrhythmias, and that they occur early in the course of treatment.
By Tom Wilemon
1 2